Elanix Biotechnologies AG

  • ISIN: DE000A0WMJQ4
  • Land: Deutschland

Nachricht vom 07.02.2019 | 14:03

Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board

Elanix Biotechnologies AG / Key word(s): Personnel/AGM/EGM
Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board

07-Feb-2019 / 14:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Elanix Biotechnologies AG: Major Shareholder requests extraordinary general assembly to replace the Chairman of the Supervisory Board

Berlin, February 7, 2019 - The new major shareholder of Elanix Biotechnologies AG ("Company", "Elanix"), Mrs. Fang Bao, has announced that she requests to convene an extraordinary shareholder meeting to replace the chairman of the supervisory board, Mr. Jürgen Kullmann.

His deputy, Mrs. Abigael de Buys Roessingh, announced today to resign from the Supervisory Board with effect from 8 March 2019. A successor should be appointed by juridical order in a timely manner.

Mrs. Fang Bao will remain in office as Supervisory Board member. A date and the agenda for the General Meeting have not yet been announced. The Management Board will keep the shareholders informed.

Lee-Ann Laurent-Applegate


Elanix Biotechnologies AG
Lee-Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.

Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

07-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this


Syzygy AG: EBIT-Prognose überfüllt, weiteres Wachstum in Sicht

Mit einer erneut außerordentlich guten Entwicklung der in Deutschland ansässigen Tochtergesellschaften war der SYZYGY-Konzern in der Lage, die Umsatzbasis auf 65,82 Mio. EUR (VJ: 60,67 Mio. EUR) auszubauen. Das Zuwachs von 8,5 % liegt leicht unter der ursprünglichen Unternehmens-Guidance eines zweistelligen Umsatzwachstums. Die Prognose einer EBIT-Marge im oberen einstelligen Bereich wurde aber voll erfüllt. Auf Basis der erreichten Neukundengewinne prognostiziert das Unternehmensmanagement für 2019 ein Umsatzwachstum in einem hohen einstelligen Prozentbereich. Das EBIT sollte um rund 10 % und damit überproportional ansteigen. Unsere Analysten sind weiter positiv für das Unternehmen mit einem Kursziel von 12,15 EUR je Aktie.

News im Fokus

Wirecard AG: Wirecard und SoftBank beabsichtigen umfangreiche strategische Partnerschaft im Bereich digitaler Paymentlösungen einzugehen

24. April 2019, 07:05

Aktueller Webcast

Royal KPN N.V.

KPN Q1 2018 Results Analyst Presentation

26. April 2019

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

24. April 2019